Antibiotic-Free Plasmid Maintenance via Toxin-Antitoxin System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current plasmid DNA vectors for gene therapy and vaccination rely on antibiotic resistance genes, which pose safety concerns due to antibiotic resistance development in bacteria and metabolic burdens, necessitating the development of antibiotic-free alternatives.
Innovation Solution
Engineering gram-negative bacteria to express a toxic gene under a tightly regulated promoter, with a plasmid encoding a cI repressor protein that inhibits the toxic gene's expression, allowing for antibiotic-free selection and maintenance of plasmids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic resistance genes are used for plasmid selection, then plasmid stability and bacterial transformation efficiency are improved, but safety risks and metabolic burdens increase
Solution Approach 1:
The patent removes the harmful antibiotic resistance gene from the plasmid system while retaining plasmid stability through a different mechanism. The selectable marker gene is extracted and replaced with a toxin-antitoxin system where the antitoxin is encoded on the plasmid and the toxin is encoded on the chromosome, eliminating the need for antibiotic resistance genes while maintaining selection pressure.
Solution Approach 2:
The patent introduces an intermediary toxin-antitoxin system to replace the direct antibiotic resistance selection mechanism. The antitoxin protein encoded on the plasmid acts as an intermediary that neutralizes the toxic effect of the chromosomally-encoded toxin, providing indirect selection for plasmid maintenance without using antibiotic resistance genes.
2Reliability
If antibiotic resistance genes are expressed constitutively, then plasmid maintenance is ensured, but metabolic burden on host cells increases
Solution Approach 1:
The patent makes the selection system dynamic by using a toxin that is constitutively expressed but its effect is modulated by the presence of the plasmid-encoded antitoxin. The system transitions from static antibiotic resistance to a dynamic toxin-antitoxin balance where plasmid maintenance dynamically regulates toxin neutralization, reducing unnecessary metabolic burden when antibiotics are not present.
3Ease of operation
If antibiotic resistance markers are used in plasmids, then selection efficiency is improved, but gene transfer to pathogens and environmental microorganisms becomes more risky
Solution Approach 1:
The patent converts the potential harm of horizontal gene transfer into a benefit by using a toxin-antitoxin system where the toxin is essential for pathogen survival. If the plasmid carrying the antitoxin gene is transferred to a pathogen, it would neutralize the toxin and potentially harm the pathogen, creating a reverse selection pressure that prevents harmful gene transfer while maintaining selection efficiency in legitimate host systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of antibiotic-free plasmids and bacteria, reducing metabolic burdens and safety risks, while maintaining plasmid stability and viability, facilitating safer and more efficient DNA vaccine production.
Implementation Method 1
a plasmid encoding a cI repressor protein that inhibits the toxic gene's expression
Implementation Method 2
Engineering gram-negative bacteria to express a toxic gene under a tightly regulated promoter
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method of maintaining a gram negative bacterium plasmid without the use of antibiotic selection pressure. Further, the invention relates to the drugless plasmids produced including drugless plasmids containing a heterologous gene. The invention also provides formulations and/or compositions comprising the drugless plasmids comprising a heterologous gene, formulations and/or compositions comprising a protein or an immunogen expressed using the drugless plasmids, and methods of administering such formulations and/or compositions to a host. The invention relates to gram negative bacteria containing the drugless plasmids.